Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What's the maximum income to qualify for wegovy financial support?

See the DrugPatentWatch profile for wegovy

There isn’t a single universal “maximum income” to qualify for Wegovy financial help. Eligibility depends on which program you’re applying to:

- Wegovy Savings Card (for people with commercial insurance): No income limit. It’s designed to reduce your out-of-pocket costs, but you must have private insurance to use it. There may be monthly caps on the savings.

- Novo Nordisk Patient Assistance Program (for uninsured or underinsured): There is an income limit. In practice, eligibility is typically tied to being at or below about 400% of the Federal Poverty Level (FPL), with the exact threshold varying by household size and the year. Other criteria also apply (e.g., lack of affordable coverage, residency). If your income is above that limit, you likely wouldn’t qualify for PAP.

How to check exactly:
- For PAP: verify current income thresholds and apply through Novo Nordisk’s patient support system or via your clinician.
- For the Savings Card: ask your pharmacist or healthcare provider about the program and how to enroll.

If you want, tell me your household size and the year you’re asking about (and your approximate gross annual income), and I can estimate where you’d fall relative to the 400% FPL thresholds to give you a rough yes/no. If you’re outside the U.S., the rules can be different, so check local program details.



Other Questions About Wegovy :

wegovy patent expiration europe How does wegovy aid weight loss? Patent on wegovy expiration? Wegovy ema approval? Wegovy 1 mg price 2023 united states list price? Wegovy ndc 0169? In what ways is wegovy distinct from other weight loss drugs?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

All substantive claims made are directly supported by the provided FDA label excerpts, including rodent thyroid C-cell tumor findings with unknown human relevance, contraindications for MTC/MEN 2, and patient counseling to report thyroid tumor symptoms.


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

WEGOVY (semaglutide) has a thyroid C-cell tumor risk in rodents, and it is unknown whether it causes thyroid C-cell tumors in humans.
Supported by Sections 5.1 and 13.1 (rodent dose- and duration-dependent thyroid C-cell tumors; human relevance unknown).
WEGOVY is contraindicated in patients with personal or family history of MTC or in patients with MEN 2.
Supported by Section 4 (contraindications) and referenced in Section 5.1.
Counsel patients to report symptoms of thyroid tumors (e.g., a lump in the neck, hoarseness, dysphagia, or dyspnea).
Supported by Section 17 (Risk of Thyroid C-Cell Tumors counseling) and Section 5.1 (symptoms examples).

Unsupported Statements


Contradictions


Important Omissions

The statement does not mention that routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection, and that elevated calcitonin may indicate MTC with recommendation for further evaluation.
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The claims provided focus on the core labeled risk (rodent thyroid C-cell tumors with unknown human relevance), the key contraindication (MTC/MEN 2), and symptom counseling; no contradictory or non-labeled safety claims were made.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Minor omission of labeled details regarding calcitonin/ultrasound monitoring uncertainty and evaluation steps for elevated calcitonin.

Suggested Improvement
If expanding the statement, include that routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value and that elevated calcitonin should prompt further evaluation.

Drug Brand Mention Assessment

Branding Score
19
Visibility
32
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

manufacturer-sponsored financial support is typically tied to household income relative to the federal poverty level (FPL)


Core Claims
  • Wegovy’s manufacturer-sponsored financial support is tied to household income relative to the federal poverty level (FPL).
  • The “maximum income” you can have to qualify depends on the specific program and current income thresholds used at enrollment.
  • Exact maximum income amount isn’t the same for everyone because thresholds can change and differ by program.
Differentiators
  • Maximum income depends on program and current enrollment income thresholds.
  • Thresholds can differ by benefit type (for example, copay support vs. patient assistance).

Pricing Perception: Not Mentioned